naltrexone and verapamil

naltrexone has been researched along with verapamil in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's5 (45.45)29.6817
2010's5 (45.45)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Fujii, H; Kobayashi, S; Miyata, Y; Nagase, H; Osa, Y; Takeuchi, T1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Lopez, J; Naujokat, P; Toledo-Pereyra, LH; Walters, W; Xavier, R1
Jing, L; Liu, C; Wang, H; Wong, TM; Wu, G; Yang, J; Yang, Y1

Reviews

1 review(s) available for naltrexone and verapamil

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

10 other study(ies) available for naltrexone and verapamil

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudi.
    Bioorganic & medicinal chemistry letters, 2011, Aug-15, Volume: 21, Issue:16

    Topics: Antimalarials; Benzylidene Compounds; Chloroquine; Drug Resistance; Molecular Structure; Naltrexone; Parasitic Sensitivity Tests; Plasmodium chabaudi; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship

2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Role of opioid antagonists in the rat liver ischemia model.
    Transplantation proceedings, 1991, Volume: 23, Issue:5

    Topics: Animals; Calcium Channel Blockers; Hepatic Artery; Ischemia; Liver; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Portal Vein; Rats; Rats, Inbred Strains; Verapamil

1991
kappa-Opioid receptor stimulation inhibits augmentation of Ca(2+) transient and hypertrophy induced by isoprenaline in neonatal rat ventricular myocytes - Role of CaMKIIdelta(B).
    European journal of pharmacology, 2008, Oct-24, Volume: 595, Issue:1-3

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Benzylamines; Calcium Channel Blockers; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Nucleus; Cell Size; Cells, Cultured; Hypertrophy; Isoproterenol; Myocytes, Cardiac; Naltrexone; Narcotic Antagonists; Propranolol; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-1; Receptors, Opioid, kappa; Sulfonamides; Verapamil

2008